enGene Therapeutics Inc. - 8-K Filing

enGene Therapeutics reports preliminary FY2026 cash position of $245.8 million and announces Phase 2 LEGEND trial results for detalimogene. (Items: 2.02 Results of Operations and Financial Condition, 8.01 below is incorporated herein by reference, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 11:14 UTC

Tickers: $ENGN

Read the full article at SEC EDGAR

Part of the story enGene Therapeutics Inc. - 8-K Filing (4 articles)

More Regulatory news

M-tron Industries, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:56 UTC
M-tron Industries, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:55 UTC
NVIDIA CORP - 8-K Filing SEC EDGAR · November 12, 2026, 13:52 UTC
COVENANT LOGISTICS GROUP, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:52 UTC
CuriosityStream Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:52 UTC
Star Equity Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:52 UTC
DeFi Development Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:51 UTC
BALTIC INTERNATIONAL USA INC - 10-Q Filing SEC EDGAR · November 12, 2026, 13:49 UTC
Forbright, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:50 UTC
Boxlight Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:50 UTC